OphthalmoPharma Ltd.

OphthalmoPharma (OPPH) is a pharmaceutical company specializing in the development of ophthalmology treatments. Our product pipeline addresses major unmet medical needs including dry eye syndrome, glaucoma, and age-related macular degeneration (AMD).

Ophthalmopharma has granted Altacor exclusive rights for its two proprietary therapeutic products for the treatment of glaucoma and dry eye as well as exclusive rights for its EyeBar, a nutraceutical for the prevention of dry AMD and the preloaded injector for delivery of intraocular lens in cataract and corrective lens replacement surgery (currently known as SOLO).

For any information concerning the licensed products, please contact Altacor, UK (www.altacor-pharma.com) for other products/matters, please contact us directly.